Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964594 | 0.91 | TRPM8 (0.48) | MAPTTP53TRPM8GAAHTT | |
| SCHEMBL4962717 | 0.91 | TRPM8 (0.53) | MAPTTP53TRPM8GAAHTT | |
| SCHEMBL4963743 | 0.88 | TRPM8 (0.59) | TRPM8NPC1RAB9A | |
| SCHEMBL4964423 | 0.85 | HTR2A (0.42) | MAPTTP53TRPM8GAAHTT | |
| SCHEMBL4963488 | 0.84 | TRPM8 (0.45) | MAPTTP53TRPM8GAANPC1 | |
| SCHEMBL3996243 | 0.84 | TP53 (0.48) | MAPTTP53TRPM8NPC1RAB9A | |
| SCHEMBL4963925 | 0.84 | TRPM8 (0.49) | MAPTTP53TRPM8GAANPC1 | |
| SCHEMBL4962720 | 0.81 | TRPM8 (0.57) | MAPTTP53TRPM8GAAHTT | |
| SCHEMBL4963522 | 0.81 | PPARG (0.43) | MAPTTP53TRPM8PPARD | |
| SCHEMBL4630463 | 0.80 | LPAR1 (0.45) | MAPTNPC1TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351858-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| EP-1517679-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB, R&D HEADQUARTERS, GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | INSR, GPR119, IRS1 | MAPT 4671/4885TP53 4383/4885TRPM8 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.